Pfizer to acquire King

Pfizer said it will acquire King Pharmaceuticals, a specialty pharmaceutical company that will build out Pfizer's pain and animal health portfolios, for $3.6 billion.

Pfizer said it will acquire King Pharmaceuticals, a specialty pharmaceutical company that will build out Pfizer's pain and animal health portfolios, for $3.6 billion.

Joan Campion, senior director of worldwide communications for Pfizer, told PRWeek that Pfizer handled communications in-house.

King Pharmaceuticals is based in Bristol, TN. It hired Ruder Finn in December 2009 to support its portfolio of pain brands, including two late-stage drugs currently in development, Acurox and Remoxy.

Pfizer said that King's products are strategically aligned with its primary care, established products, and animal health business units. King acquired animal health company Alpharma in 2008, which allowed King to expand its pain portfolio to include the Flector pain patch. 

An analyst told The New York Times that King's assets: "may potentially perform better under Pfizer's umbrella, in our view, given Pfizer's strong marketing machine.”

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.